– Re-branded company name to Rakuten Medical, Inc.
– Completion of Phase 1/2a Part II for RM-1929 in Recurrent HNSCC to evaluate repeated treatments.
– Designation under the SAKIGAKE designation system for ASP-1929 in HNC.
– Rakuten Medical subsidiary established in Taipei, Taiwan and Amsterdam, Netherlands
– Released Phase 2A study data for RM-1929 in Recurrent HNSCC during ASCO annual meeting.